A strategic decision made nearly a decade ago to halt a specific type of federal health care reimbursement has unexpectedly spiraled into one of the most significant fiscal paradoxes within the Affordable Care Act, costing taxpayers billions more than the original program it was meant to curtail.
Beyond the sterile confines of the laboratory and the static lines of an electronic health record, a new currency is emerging that promises to fundamentally reshape the economics and practice of medicine. This asset is not a new drug or a revolutionary surgical device, but rather the vast and
Navigating the complex regulatory maze for a first-in-class therapy just became significantly clearer for Plus Therapeutics following a pivotal meeting with federal regulators that charted a definitive course for its lead drug candidate. The company has announced the outcomes of a constructive Type
A groundbreaking legislative mandate is set to fundamentally reshape the landscape of emergency medical response across New York, compelling a system-wide reevaluation of services long strained by critical resource and personnel shortages. For years, communities have grappled with a patchwork
The once-clear line separating clinical practice from business strategy has effectively dissolved, compelling medical institutions to recognize that the journey to patient care no longer begins with a referral slip but with a search query. In an environment where patients are empowered consumers
A class of drugs once quietly confined to the clinical management of diabetes has forcefully breached the walls of traditional healthcare, creating a multi-billion dollar cultural and commercial phenomenon that is reshaping the pharmaceutical landscape. Glucagon-like peptide-1 (GLP-1) receptor
